The market to sell government-subsidized infant vaccines in the US is vast. And Merck will now likely be in a leadership position for RSV in the newborns setting. [This, even as the moron Kennedy offers deeply misinformed views on vaccines, generally.] Here is the latest, via Reuters:
. . .The U.S. Food and Drug Administration on Monday approved Merck's preventive [mRNA vaccine] shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said.
Merck's monoclonal antibody, called clesrovimab and branded as Enflonsia, is the first and only preventive shot that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. The company told Reuters the therapy will be priced at $556 per dose. . . .
As I said at the top -- this is a vast and growing market in the US. Excellent, for Merck -- and for human health generally.
नमस्ते
No comments:
Post a Comment